Advertisement
Longbio-b

Longbio-b (1779.HK) Stock Overview

Explore Longbio-b’s financial performance, market position, analyst ratings, and future outlook.

1779.HKHKSE
HealthcareBiotechnology
HK$150.00
HK$7.20(4.58%)
Hong Kong Market opens in 39h 45m
Advertisement

Longbio-b (1779.HK)

Meyka AI Score

Z

Key Financials

Market Cap10.9B
P/E RatioN/A
EPS (TTM)$-2.65
ROEN/A
Fundamental Analysis

AI Price Forecasts

1 Month$55.16
3 Months$210.53
1 Year TargetN/A

1779.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Longbio-b (1779.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 56.91, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 10.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-4.58%
5-Day Change
5.04%
1-Month Change
13.81%
3-Month Change
13.81%
6-Month Change
13.81%
Year-to-Date (YTD) Change
13.81%
1-Year Change
13.81%
3-Year Change
13.81%
5-Year Change
13.81%
All-Time (Max) Change
13.81%

Contact Information

NaN
Building F, Area A, Suzhou, NaN, 215500

Company Facts

850 Employees
IPO DateJun 5, 2026
CountryCN
Actively Trading

Frequently Asked Questions